{"disease":{"id":"gastro-esophageal-reflux-disease-with-esophagitis","name":"Gastro-esophageal reflux disease with esophagitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lafutidine","indication_name":"Gastro-esophageal reflux disease with esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Protecadin","generic_name":"LAFUTIDINE","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"lafutidine","quality_score":10,"revenue":null,"mechanism":"Protecadin works by blocking histamine H2 receptors to reduce stomach acid production."},{"drug_id":"revaprazan","indication_name":"Gastro-esophageal reflux disease with esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revanex","generic_name":"REVAPRAZAN","company_name":"","drug_phase":"marketed","molecular_target":"Potassium-transporting ATPase","drug_class":"revaprazan","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"camostat","indication_name":"Gastro-esophageal reflux disease with esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CAMOSTAT","company_name":"","drug_phase":"discontinued","molecular_target":"Serine protease hepsin","drug_class":"camostat","quality_score":null,"revenue":null,"mechanism":"CAMOSTAT works by blocking the activity of hepsin, a protease that contributes to inflammation and tissue damage."},{"drug_id":"takecab","indication_name":"Gastro-esophageal reflux disease with esophagitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Takecab","company_name":"Genuine Research Center, Egypt","drug_phase":"phase_1","molecular_target":"Potassium-transporting ATPase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04248296","title":"Evaluate the Intestinal Microbiome in Patients With Erosive Gastroesophageal Reflux Disease and in Asymptomatic Healthy Controls","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}